Abstract 19P
Background
County-level hospitals, as the "gatekeepers" for rural cancer patients (pts) in the hierarchical diagnosis and treatment system (HDTS) in China, shoulder significant responsibilities in facilitating cancer treatment and patient referrals. Here, we report the referral data from the CHASE001 trial (NCT05544123).
Methods
CHASE001, a prospective, non-interventional multicenter study exploring real-world treatment and referral practices among pts in Chinese county-level hospitals with HER2+ or HR+/HER2- breast cancer (BC) is ongoing since Sep. 2022. The primary endpoint is to describe the treatment patterns. A key secondary endpoint is referral behavior. Descriptive statistics were utilized to analyze the referral data.
Results
At data cutoff (May 17, 2023), 1436 BC pts were included from 26 county-level hospitals in China. 1172 (81.62%) pts were initially diagnosed at county-level hospitals, among them, 81 (6.91%) pts were subsequently referred to higher-level hospitals. 58 out of 81 pts were referred out primarily to receive breast surgery (71.60%), and most of them were eventually referred back to county-level hospitals to receive adjuvant systemic treatment (94.83%, 55/58). Among 264 pts who were initially diagnosed at higher-level hospitals, a significant portion (84.09%) were referred to county-level hospitals to receive adjuvant systemic treatment. The majority (75.99%, 1092/1436) underwent the entire process of diagnosis and treatment within the county-level hospitals without requiring referral-out, however. Among 341 pts who received treatment at higher-level hospitals, 153 (44.87%) brought back their treatment plan to county-level hospitals, and the majority (90.20%, 138/153) adhered to that treatment plan. Interestingly, pts with higher education levels, and employee medical insurance were more inclined to seek treatment at higher-level hospitals, primarily to recieve breast surgery and neoadjuvant treatment.
Conclusions
Most of the patients admitted to county-level hospitals in China underwent the entire process of diagnosis and treatment within these hospitals, indicated that further efforts to provide high quality, guideline centric care should be concentrated at county-level hospitals.
Clinical trial identification
NCT05544123.
Editorial acknowledgement
Legal entity responsible for the study
P. Lu.
Funding
AstraZeneca.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
88TiP - A phase Ib study of HMBD-001, a monoclonal antibody targeting HER3, with or without chemotherapy in patients with genetic aberrations in HER3 signaling
Presenter: Nick Pavlakis
Session: Poster Display
Resources:
Abstract
93P - Efficacy and safety of fruquintinib (F) + best supportive care (BSC) vs placebo (P) + BSC in refractory metastatic colorectal cancer (mCRC): Asian vs non-Asian outcomes in FRESCO-2
Presenter: Daisuke Kotani
Session: Poster Display
Resources:
Abstract
94P - Sidedness-dependent prognostic impact of gene alterations in metastatic colorectal cancer in the nationwide cancer genome screening project in Japan (SCRUM-Japan GI-SCREEN)
Presenter: Takeshi Kajiwara
Session: Poster Display
Resources:
Abstract
95P - Interim results of a prospective randomized controlled study to compare the clinical outcomes of total neoadjuvant therapy vs long course chemoradiotherapy in locally advanced carcinoma rectum
Presenter: Sandip Barik
Session: Poster Display
Resources:
Abstract
96P - Tyrosine kinase inhibitor (TKI) plus PD-1 blockade in TKI-responsive MSS/pMMR metastatic colorectal adenocarcinoma (mCRC): Updated results of TRAP study
Presenter: Jingdong Zhang
Session: Poster Display
Resources:
Abstract
97P - Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
Presenter: Rui-Hua Xu
Session: Poster Display
Resources:
Abstract
98P - Real clinical impact of postoperative surgical complications after colon cancer surgery
Presenter: Toru Aoyama
Session: Poster Display
Resources:
Abstract
99P - Extended lymphadenectomy may not be necessary for MSI-H colon cancer patients after immunotherapy
Presenter: Rongxin Zhang
Session: Poster Display
Resources:
Abstract
100P - Identification of phenomic data in the pathogenesis of colorectal cancer: A UK biobank data analysis
Presenter: Shirin Hui Tan
Session: Poster Display
Resources:
Abstract
101P - The coexistence of TP53 gain-of-function mutation and hypermethylation as a poor prognostic factor in BRAF wild-type metastatic colorectal cancer
Presenter: Kota Ouchi
Session: Poster Display
Resources:
Abstract